Does the Use of Immunosuppressive Drugs Impact on SARS-CoV-2 Infection Outcome? Data From A National Cohort of Patients With Immune-Mediated Inflammatory Diseases (SAR-COVID Registry)

Isnardi, C. A.; Soriano, Enrique R.; Graf, César; Vega, María Celina De la; Pons-Estel, Bernardo A.; Roberts, Karen; Quintana, Rosana; Gómez, Gimena; Yazdany, Jinoos; Saurit, Verónica; Báez, Roberto Miguel; Coello, Vanessa Viviana Castro; Pisoni, Cecilia; Berbotto, Guillermo; Vivero, Florencia; Zelaya, Marcos David; Salinas, María Jezabel Haye; Torres, Alvaro Andres Reyes; Ornella, Sofía; Nieto, Romina; Maldonado, F.; Gamba, María Julieta; Severina, María de los Ángeles; Tissera, Yohana; Paula, Alba; Cogo, Adriana Karina; Alle, Gelsomina; Gobbi, Carla; Baños, Andrea; Velozo, E.; Pera, Mariana; Tanten, Romina; Albiero, J. A.; Schmid, Maria Marcela; Martire, María Victoria; Elkin, M. S. Gálvez; Cosatti, M.; Cusa, María Alejandra; Pereira, Dora; Savio, V.; Pons‐Estel, Guillermo J.

doi:10.1097/rhu.0000000000001903

Cited by 2 publications

(2 citation statements)

References 28 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Details of the design of the SAR-COVID Registry, from Argentina, the CMR-COVID Registry, from Mexico, and the ReumaCoV-Brasil Registry, from Brazil have been described previously. [6][7][8] Briefly, SAR-COVID is a national, multicenter, observational, voluntary registry including adult patients with a rheumatic disease and confirmed SARS-CoV-2 infection. 7 A total of 143 independent rheumatologists from all over Argentina have registered to participate.…”

Section: Registry Designsmentioning

confidence: 99%

“…[6][7][8] Briefly, SAR-COVID is a national, multicenter, observational, voluntary registry including adult patients with a rheumatic disease and confirmed SARS-CoV-2 infection. 7 A total of 143 independent rheumatologists from all over Argentina have registered to participate. All variables were collected by self-report, clinical and laboratory examination and/or medical records review, performed by the rheumatologist during patient hospitalization due to COVID-19, or at the patient medical appointment (virtual or face-to-face) performed after SARS-CoV-2 infection, depending on availability.…”

Section: Registry Designsmentioning

confidence: 99%

See 1 more Smart Citation

Factors Associated With Mortality in Patients With Immune-Mediated Rheumatic Diseases and COVID-19 From Latin America

Isnardi,

Alpizar-Rodriguez,

Calderaro

et al. 2023

J Clin Rheumatol

Self Cite

View full text Add to dashboard Cite

Objective To describe characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in patients with rheumatic immune-mediated inflammatory diseases (IMIDs) from Argentina, Mexico and Brazil, and to assess factors associated with mortality in this population. Methods Data from 3 national registries, SAR-COVID (Argentina), CMR-COVID (Mexico), and ReumaCoV-Brasil (Brazil), were combined. Adult patients with IMIDs and SARS-CoV-2 infection were recruited. Sociodemographic data, comorbidities, IMID clinical characteristics and treatment, and SARS-CoV-2 infection presentation and outcomes were recorded. Results A total of 4827 individuals were included: 2542 (52.7%) from SAR-COVID, 1167 (24.2%) from CMR-COVID, and 1118 (23.1%) from ReumaCoV-Brasil. Overall, 82.1% were female with a mean age of 49.7 (SD, 14.3) years; 22.7% of the patients were hospitalized, and 5.3% died because of COVID-19 (coronavirus disease 2019). Argentina and Brazil had both 4% of mortality and Mexico 9.4%. In the multivariable analysis, older age (≥60 years; odds ratio [OR], 7.4; 95% confidence interval [CI], 4.6–12.4), male sex (OR, 1.5; 95% CI, 1.1–2.1), living in Mexico (OR, 3.0; 95% CI, 2.0–4.4), comorbidity count (1 comorbidity: OR, 1.5; 95% CI, 1.0–2.1), diagnosis of connective tissue disease or vasculitis (OR, 1.8; 95% CI, 1.3–2.4), and other diseases (OR, 2.6; 95% CI, 1.6–4.1) compared with inflammatory joint disease, high disease activity (OR, 4.2; 95% CI, 2.5–7.0), and treatment with glucocorticoids (OR, 1.9; 95% CI, 1.4–2.5) or rituximab (OR, 4.2; 95% CI, 2.7–6.6) were associated with mortality. Conclusions Mortality in patients with IMIDs was particularly high in Mexicans. Ethnic, environmental, societal factors, and different COVID-19 mitigation measures adopted have probably influenced these results.

show abstract